Pathology State of the Department - Nov. 13, 2025

Name: Pathology State of the Department - Nov. 13, 2025
Uploaded: 2026-02-20T22:37:10.9533333Z
Duration: 1 h 8 min
Description: Pathology State of the Department, Chen Liu, MD, PhD, chair of Yale Pathology.

February 20, 2026

Pathology State of the Department, Chen Liu, MD, PhD, chair of Yale Pathology.

Information

ID: 13865
To Cite: DCA Citation Guide

Download Transcript

00:02Good afternoon, everyone.
00:06Yeah. Good afternoon, everyone. Thank
00:08you for coming.
00:10So this is,
00:12the
00:13annual conversation to the state
00:14of department.
00:16And, I will just, you
00:17know, present what's, you know,
00:20some of the highlights.
00:22And,
00:23before,
00:24we begin, so I would,
00:26like everybody to join me
00:28and,
00:29have a take a moment
00:31of silence to really honor
00:33our really beloved
00:35long time professor, doctor Michael
00:37Kashkarin,
00:38who passed away this year.
00:48Thank you.
00:50So big
00:53oh, okay. This, you know,
00:55we have done that before.
00:57Basically, the chair will do
00:59the annual presentation
01:01to basically,
01:02you know,
01:04update provide updated information about
01:06the department.
01:08The objective
01:09is really to
01:10know the the current state
01:12of the department, you know,
01:13the opportunities, achievements, challenges, and,
01:17obstacles.
01:18And now also, we'll provide
01:20some highlights
01:22in our
01:23key mission area, which, you
01:24know,
01:25is a research,
01:26patient care, education, and the
01:29community service.
01:31Then we will really discuss,
01:34you know, from all of
01:35this information, thinking about how
01:36to
01:37sustain and to build our
01:39success and con
01:40you know, in the next
01:42year.
01:43So I always start with
01:45this,
01:46fact sheets about our department.
01:48So I sometimes
01:49this is a cable changing.
01:51It's dynamic information. The cutoff
01:53for this one is
01:54really, June thirtieth,
01:57twenty twenty,
01:58five because we are talking
02:00about this academic year for
02:02twenty twenty five. So I
02:03have total of four hundred
02:04sixty six members in the
02:06department.
02:07So our primary faculty is
02:08one hundred forty eight and
02:10a staff member two zero
02:12two zero six, and we
02:13have trainees, trainees including clinical
02:15fellows, pathology residents, and the
02:17post op fellows.
02:19And, also, we have a
02:20class, you know, of graduate
02:21students for PhD for PhD
02:24degrees,
02:25but we have thirty six.
02:26So our department provides,
02:28you know, services to
02:30three main hospitals. One, the
02:32most you know, the biggest
02:33the biggest one, the flagship
02:34hospital
02:35is Yoni Hills
02:37Hospital, and which has two
02:38campuses,
02:39York campus and SRC,
02:41and also provide services for
02:43Bridgeport Hospital and also Milford
02:46Milford Hospital.
02:49So just a a reminder
02:51for what is our vision
02:53and the mission of the
02:54department.
02:55So our vision is to
02:56to become a destination place
02:58for research, education, and patient
03:00care. So our mission is
03:01really continue our history of
03:03of world class patient
03:05care, innovative and impactful research
03:08and rigorous training for
03:11the next generation of pathologists
03:13and also scientists.
03:16So here is the really
03:17the executive leadership team.
03:20I myself, I know we
03:21have three vice chairs and
03:23doctor Daisy,
03:24for for clinical affairs, doctor,
03:26Levi
03:28runs for clinical operation and
03:30reference program. Doctor David Stern
03:32is run in running our
03:34research program. And then we
03:36have the director,
03:37the Dimas,
03:38Bataklia, who is the director
03:40for administration
03:41and business.
03:43Now also, Donna,
03:45Eisenberg,
03:46who is the senior director,
03:49on the IBO,
03:51on the IBO side.
03:54So it's always exciting to
03:56welcome new members of the
03:57department.
03:58So here we have, you
04:00know, out as a cutoff
04:01date of June thirtieth twenty
04:03twenty five, we have nine
04:05new faculty members.
04:07But, also after that, we
04:09have additional five faculty members
04:11are here, so I will
04:12acknowledge them again next time.
04:14But here, at least their
04:15name. I'm not going to
04:16read all the name. This
04:17is just, you know, of
04:19of facts.
04:20So those are new faculty
04:21members, both clean on the
04:23clinical side and also on
04:25the, you know,
04:26research
04:27side. So I for this
04:29faculty member, I just listed
04:31mainly on the lighter fifty
04:32members. We certainly have many
04:35other research, like, faculty members
04:37as well. So I you
04:39know, we are now listed
04:40here.
04:41So on the staff side,
04:43you know, in physical twenty
04:44five, we recruited twenty eight
04:47new staff members. Those are
04:49the names, not intended to,
04:51you know, to be right.
04:52I just state the facts
04:53as well.
04:56So we have two five
04:58faculty members
04:59got promoted,
05:00doctor Dimitris
05:02Brightock promoted to full professor,
05:05effective July first twenty twenty
05:07four, and the doctor Palavi
05:08Gopal promoted to associate professor
05:11effective July first twenty twenty
05:12four. So this will be
05:13fall into the physical twenty
05:15five academic year.
05:18And then we
05:20also have our the inaugural,
05:23Louis Zenharbour, MD professorship
05:25named, you know, doctor David
05:27Klimstra,
05:28professor of pathology,
05:29who was named as the
05:31inaugural
05:32Lewis and Harvard professorship.
05:36And now we named the
05:38two Virginia Swanson scholars. This,
05:41scholar is for
05:43for junior fact, you know,
05:44basic for assistant professor and
05:46early stage associate professor.
05:49The, doc, doctor Pohan Chang,
05:51assistant professor,
05:52was named as a
05:54Virginia Swanson scholar, and now
05:56doctor Declan Magoon,
05:59is associate professor is also
06:01named,
06:02as Virginia Swanson scholar.
06:06So at same time, we
06:07know also we have some
06:08faculty departure and,
06:11and also retirement.
06:13So this year, we have
06:14four faculty members retired
06:16from a long terms, you
06:17know, from, some of them
06:19with long term services
06:21to the department. You know,
06:22really, really we are really
06:24grateful for their contribution
06:26to our mission.
06:27Doctor Earl Lusack,
06:29doctor Peter Humphrey, doctor,
06:31Joe Mastrategy, and doctor,
06:34Manju Persad. Those four professors
06:36are retired,
06:37but some of them will
06:39continue to be with us.
06:40I serve as a senior
06:41research scientist.
06:43So we have one faculty
06:44member,
06:45moved to, Stony Brook University,
06:49and he took this new
06:50opportunity to serve as a
06:52AP director and the vice
06:54chair for that department pathology.
06:58So as I said,
06:59we really follow this attrition
07:01rate because that's what I
07:03believe is a good indication
07:05on our overall environment is
07:07our attractiveness.
07:09But I have to say
07:10we really thank our faculty
07:11for their loyalty and the
07:13to serve in this department.
07:15So those are the over
07:16the every year, you know,
07:18you know, but we've somehow
07:19we are around, like, a
07:20four to five percent attrition
07:22rates. This is including retirement,
07:24departure,
07:26you know, from the department.
07:28I think at a national
07:29level, you see the rate
07:30is around ten to fifteen
07:32percent. We still have very
07:33good
07:34retention rate for our faculty.
07:37I think, really appreciate appreciate
07:39for all your,
07:41faith all your face in
07:42our department.
07:44At same time, I also
07:46attract the staff attrition rate.
07:47This is including all our
07:49technical,
07:51employees.
07:53You last year, for whatever
07:54is this, the lowest ever
07:56physical twenty five, we only
07:57have one percent attrition rate
07:59for the on the staff
08:00side. As you you know,
08:01in this category, the national
08:03data is around eighteen to
08:05twenty percent attrition rate because
08:07those are really challenging for
08:08many places you probably
08:10heard, and that they will
08:11have staff shortage to support
08:13the clinical library service.
08:15So we're really, you know,
08:16grateful and thanks for every
08:18members of the department
08:20for, you know, you know,
08:21for
08:22their dedication
08:24to our department.
08:26Alright. So now today, we
08:28do a turn down that
08:29we do have, this is
08:30our third year for our
08:32strategic
08:34plan.
08:34So we came out this
08:35plan in twenty twenty two.
08:37So this, you know, this
08:39is a five year planning.
08:41I know I talked about
08:42the last two time. So
08:43I'm not going to talk
08:45about it in detail in
08:46this
08:47particular,
08:48presentation.
08:49But the thing is, I
08:51have we'll we'll dedicate some
08:52time today and talking about
08:55the Yale School of Medicine's
08:56strategic
08:57planning because we have to
09:00also thinking about how to
09:01align with the school and
09:03with,
09:04you know, in terms of,
09:05you know, their strategy planning.
09:07And amazingly, so our strategy
09:09is planning is really aligned
09:11very well with the YSM,
09:14the strategy plan. So that's
09:15why I wanna hear I
09:16just wanted to, you know,
09:19update you on those schools.
09:21YSM, you know, strategy plan.
09:24It's divided into research
09:26strategy and the clinical strategy.
09:28For research strategy,
09:30you know, the school wants
09:31to add one of the
09:32science of healthy, you know,
09:33healthy aging. You know, we
09:36have the YH,
09:38your center in our institute
09:39under, Dixie. I think he
09:41just got
09:42presented to the dean's advisory
09:44board about a few minutes
09:45ago. He's here now.
09:47But, so this is a
09:49fantastic
09:50center. So we really align
09:52well with the schools,
09:53strategic,
09:54planning.
09:55And also school want to
09:57coordinate the effort in neuroscience,
09:59neuroinflammation,
10:00neurodegeneration
10:01behavior, and the brain science
10:02and autism. This is a
10:04school's,
10:05you know, priority disease area.
10:06You know, we have how
10:08our faculty,
10:09many of our existing faculty
10:10or some of the new
10:11recruit
10:12really engaging in inflammation, particularly
10:14neuro inflammation,
10:16neurodegenerative
10:17disease so that we are
10:19aligned with school. And also
10:21genetic of rare disorders,
10:23develop a novel therapies and
10:25the, you know, passive physiology.
10:26We do have our faculty
10:28working on the rare diseases,
10:29genetic diseases,
10:31developing
10:32therapies, and the leading,
10:33in development of a data
10:35science, AI, bioinformatics.
10:37I think we have a
10:38lot of activity
10:39here, you know, including Steve
10:41Kleinstein, your Google, and also
10:43we recorded,
10:45YAR,
10:46this this year and to
10:47really beef up our, you
10:48know, bioinformatic
10:50and the data science,
10:51section.
10:52And personalized medicine for complex
10:55disease, including AI, genetic,
10:57genomic risk prediction to pre
11:00to improve health for all.
11:01Because this is a really,
11:03you know, to our central
11:05mission because we are in
11:06the,
11:07pathology. We do the all
11:08the molecular diagnosis really supporting
11:10the precision medicine. So we
11:12align from all those, you
11:14know, really,
11:16aligned well with the school's
11:17research strategy.
11:19So there are some cross
11:20cutting themes on the school
11:22side. So what is school
11:24is promoting? Why is it
11:25facilitate a multidisciplinary
11:27research,
11:29particular focusing on the chi,
11:32priority disease area, neuroscience, immunobiology,
11:35metabolism,
11:36cardiovascular,
11:37and the cancer. So we'll
11:38focus the,
11:40studies and the groups. So
11:42we all, you know, have
11:44in our faculty collaborate very
11:46well and actually
11:47participated in many some disease
11:50centers in in a school.
11:51And also enhanced communication and
11:53education
11:54increase increase
11:56knowledge of an access resources.
11:58So those are also,
12:00it's a cutting edge thing.
12:02And, a very important part
12:04is the school is advocates
12:06for diversifying,
12:07finding sources for research. This
12:09is also one of the
12:10priority area for our department.
12:12I will talk about a
12:13little bit more later.
12:15And also a a salary
12:16the integration and expansion of
12:18a biorepository
12:19linked to the clinical data
12:21repository.
12:22So we are really playing
12:24leading role in supporting the
12:26Yale School of Medicine's,
12:28you know, central biorepository.
12:31And,
12:32also co create, implement research
12:34for community health in collaboration
12:37with the health systems
12:39and achieve administrative
12:40excellence to reduce burden
12:43on pre and post award
12:45management to facilitate
12:46efficient contracting regulated process. But
12:49we all know at least
12:51school is making, emphasize on
12:53that. There's a lot of
12:55work needs to be done
12:56in this area. We all
12:57we all understand a particular
12:58related to the contract and
13:00regulatory issues. And then also,
13:03you know, school is really
13:04emphasizing and enhancing institutional
13:06support for physician scientists
13:08and the science development.
13:10So you can clearly see,
13:11you know, the schools' research
13:12strategy. We what our existing
13:16departmental strategy is really aligned
13:18very well with the school
13:20strategy.
13:21And then for the clinical
13:22strategy, even more so aligned
13:24with the school and that
13:25we you will have a
13:26lot of to talk about
13:27that today. Basically, it's a
13:28better engaging and empower clinical
13:30leaders and faculty in aligned
13:32academic health system. It's getting
13:34more and more aligned. That's
13:35the key word, alignment between
13:37the school and the the
13:38health
13:39system. And that leverage our
13:40differentiators to create an innovative
13:42new business and diversify revenue
13:44in the setting with clinical
13:46disruption. So this is really
13:48the main focus for our
13:50reference testing program and also
13:52potential many other new opportunity
13:55new opportunity we need to
13:56consider.
13:57And also part,
13:59support the career development of
14:01clinicians
14:02and the other ones, the
14:02application of precision medicine and
14:05AI in the academic health
14:06system. Those are the schools'
14:08clinical,
14:09strategy. What I'm by now,
14:12you see, we have really
14:13we are our strategy plan
14:15is still working. However, we,
14:18like everything else, once in
14:19a while, we needed to
14:20thinking about rethinking
14:22or refreshing our strategy. So
14:24now we're in the, we're
14:27our leadership is working on
14:28our current strategy plan again.
14:31Hopefully, in the next few
14:32months, we plan to have
14:34a faculty retreat and focusing
14:36some of the, you know,
14:39the priorities in our strategy
14:40plan. And hopefully, we you
14:42know, for the next few
14:43years, then the guide us
14:44through this process.
14:47Alright. So now I highlight
14:48a few things, but I'm
14:50not sure this is the
14:51the only benchmark, but I
14:52think it was a pretty
14:53good one we will take.
14:55So as you know, this
14:56is the NIH funding at
14:56a national level. The the
14:58Yale School of Medicine is
15:00the number three in the
15:01country, and our department, you
15:03know, this is the highest
15:04ever is the number six
15:05in the country. But I
15:06have to say this also
15:07include the laboratory medicine, and
15:09I think we finally get
15:10a pathology and laboratory medicine
15:12grant portfolio together because bridge,
15:15you know, we call the
15:16bridge,
15:18blue bridge,
15:19blue, rich, but ranking include
15:21only ranking pathology, but they
15:23include in laboratory medicine. So
15:25the laboratory medicine is part
15:27of it. So that's why
15:27we kinda getting our ranking
15:29high. Thanks for all the
15:31faculty members who, you know,
15:32actively pursue an age grant.
15:34But this is some really,
15:37honor to to to help.
15:39Hopefully, we we keep it
15:41and also grow it. Let's
15:43shoot up to the top
15:44of three. You
15:45know? There are some names
15:47down there we know that
15:48we we need to work
15:49harder to achieve the top
15:51three.
15:53Alright. So our department research
15:55highlights, you know, I would
15:57just say that some of
15:58the key papers, this is
15:59really, we selected, but no
16:01by no means and the
16:02way this are the only
16:04one. They are I'm pretty
16:05sure there were some other
16:06paper, you know, papers
16:08or research,
16:09findings that we'll miss. But
16:11how so,
16:12I I apologize if I,
16:13you know, did did not
16:14stay you are just discovering.
16:17So basically, a few important
16:18thing, we would you know,
16:19RIMS lab had you know,
16:21is doing this novel biomarkers
16:24for breast cancer.
16:25And,
16:27you know, Schauffer's lab discovered
16:29a new mechanism for lung
16:30cancer immune evasion.
16:32And,
16:34you know, Dixie's lab really
16:35discovered this nerve associated macrophages
16:38in aging and the potential
16:39inflammation is a really key
16:41point.
16:42And, also also, like, you
16:43know, discovered this new mechanism
16:45for DTT forty three regulating
16:47RNA,
16:48in neurons.
16:50And the downwind slide, it
16:51is a very interesting one
16:53and identify a really master
16:55regulators called the, night ten
16:57and, you know, guide or
16:59control the brain the cancer
17:01brain metastasis.
17:03And, you know, doctor, Karakati
17:06is typing to identify this
17:07project,
17:08regenerative phenotype in the thrombin
17:11thrombosed bounding to deficient the
17:13fibroblasts,
17:14you know, involved in the
17:15healing.
17:16So my own lab, you
17:17know, we haven't developed a
17:18new vaccine for COVID nineteen,
17:20which I protect which is
17:22the only one now actually
17:24produce local mucosal immunity against
17:27the SARS two.
17:30So some other highlights is
17:32really seeing our faculty member
17:34are heavily involved in cancer
17:36center.
17:36So, you know, it's great
17:38news. The CCSG, you know,
17:39competing renewal has been funded.
17:42And then the other thing
17:43is, you know, it's another
17:44competitive
17:45renewal for the lot e
17:47l spall in lung cancer.
17:49So,
17:50doctor Katie,
17:52Palote is the co director
17:53for this lung spore. It's
17:55also got funded.
17:58Again, our faculty has been
17:59heavily in the other spore,
18:01you know, like high the
18:02neck spore and the melanoma,
18:04skin cancer spore.
18:05And then the other really
18:07highlight is we just had
18:08a very successful, you know,
18:10second YH Symposium
18:12and,
18:13you know, organized by doctor
18:15Deepa
18:16Dixie. So it really attracted,
18:18you know, hundreds of, you
18:20know, attendance.
18:22It was a fantastic
18:23symposium.
18:25On the clinical side, so
18:26we really, you know, completed
18:28the,
18:30operational and the professional integration.
18:33You know, you keep the
18:33keyword alignment, the integration efficiency
18:36on the clinical side is
18:37really our keyword. So the
18:39integration of subspecial
18:41especially the service between, you
18:42know, pathology may basically in
18:44New Haven and the bridge
18:45part at, you know, with
18:47all the the subspecial, the
18:48name, the cytopathology,
18:50GI, thoracic,
18:51and the bone soft tissue.
18:53And also successful implemented SRC
18:55remote frozen section. This is
18:57another milestone because we finally
18:59have the, you know,
19:01remote coverage for,
19:03SRC in terms of frozen.
19:04This is really an also
19:06setting a stage for future
19:08remote frozen section coverage.
19:10And also completed a technical
19:13validation for remote,
19:14you know, called the ROS
19:15rapid on-site
19:17evaluation,
19:18you know, at a false
19:19SRC and a bridge power.
19:21And,
19:23the other is the problem
19:24thing we'll talk about is
19:25really getting the,
19:27resign out scanning. Basically, it's
19:29a part of the digital
19:30pathology implementation in our department.
19:32So I can talk a
19:33little bit more, in the
19:35next few seconds.
19:37So in terms of clinical,
19:39operation, so basically, we have
19:41tried everything to standardize
19:43system and
19:44system alignment
19:46to really eliminate all the
19:47redundancy tests and the pathology
19:50and left laboratory medicine. And
19:51the central you know, for
19:53one perfect example is really
19:55centralized
19:56primary HPV molecular testing
19:58for cervical cancer for the
20:00entire health system. Now the
20:02Yale, our laboratory is the
20:04only laboratory
20:05you know, to perform the
20:06HPV primary screening for the
20:08entire health system. This is
20:09a really remarkable
20:11milestone, and I will think
20:12this is a critical.
20:14And we're developing some all
20:15more automatic process, like a
20:17bar coding,
20:18for slide filing,
20:20full transcription
20:22full transitional pathology transcription to
20:24voice recognition.
20:25This is the first time
20:26we don't have
20:28transcriptionist
20:29anymore. So those are really
20:31some citing that, you know,
20:32it's really, really critical. It's
20:35a difficult thing to do,
20:36but it's now we have
20:37the full voice recognition system.
20:39And then we certainly the
20:41digital,
20:42thought transformation and workflow for
20:44the clinical service is ongoing,
20:46but it has achieved its
20:47initial goal. And as right
20:49now, for example, the tumor
20:51part, you you know, immunohistochemistries,
20:53and some of the biopsy
20:55placements, it's all
20:57scanned digitally,
20:58and the part you know,
20:59some of the faculty already
21:00doing digital sign out. So
21:02this was another milestone. I
21:04think it can get
21:06more and more. So our
21:07immunohistochemistry
21:08lab right now, you know,
21:09we have a new director.
21:10It's a doctor Luo,
21:12Wenyu Luo is now the
21:13new director, succeed at doctor,
21:15Joe Masrachi after retirement.
21:18So we continue to develop
21:19new markers and, you know,
21:21particularly focusing FDA approval of
21:23new markers, you know, which
21:25will have a therapeutic implications
21:27then for those, you know,
21:28those, markers will continue to
21:30develop. So the central seam,
21:32as I mentioned, on the
21:33clinical side, is really building
21:35cross side, cross functional partnership,
21:39across the, you know, the
21:40entire house system. And that
21:43those curve for the purpose
21:44is really driving the operational
21:46strength in enabling scalable,
21:49solutions. This is really the
21:51thing. You know, we have,
21:52you know, seven hospital in
21:53the health system. So, really,
21:55it's brand new geographically.
21:56So this is where we
21:58can continue to do more
21:59and find the opportunity
22:01to further grow
22:02our operation.
22:04So I mentioned digital pathology
22:06and AI pathology. This is
22:08the future of pathology. It's
22:10also
22:11now is, you know, is
22:12in action. So,
22:14I'm really glad that we
22:15recruited doctor David Klims to
22:17serve as a chief strategist
22:19for our digital pathology and
22:21AI implementation.
22:22And we have a Sudhir
22:24pen
22:25Perincheri to serve as the
22:26director,
22:27And then we have a
22:27fantastic manager, Carol Hyde, and
22:30to, you know, to really,
22:31you know, operationalize the digital
22:33pathology.
22:34Right now, we have
22:35three scanners. Two scanners are,
22:38in New Haven, one scanner
22:39at the Bridgeport.
22:41And, I think the other
22:42four scanner, you know, I
22:44think is on the way
22:45to we're going to have
22:46more scanners coming to, you
22:47know, online in a short
22:49term in the next few
22:50months, hopefully. And then we
22:52have a one grand in,
22:53grand in another mobile,
22:56digital scanner. This is one
22:57for frozen section coverage.
23:00This is the one we
23:01are currently using to cover
23:02bridge part, for for SRC
23:04canvas. And then we have
23:05the remote microscope
23:07microscope and then really do
23:09the on-site evaluation.
23:11And, the other thing is
23:12we are in the process
23:13to acquiring the AI assist
23:15the process of the biopsy
23:16platform. This is the only
23:19FDA approved platform to use
23:21AI to help, you know,
23:23reading,
23:24help review,
23:26the prostate biopsy to for
23:28cancer detection. Those are coming
23:30very soon.
23:32So the biggest thing, as
23:34you know, we are switching
23:36our,
23:37in for,
23:38basic laboratory information system, the
23:40LS system. So we have
23:43made the decision. We'll transition
23:45the IPIC to beaker.
23:47You know, the timeline is
23:49full next year. We We
23:51are currently doing that. Is
23:53that everything is ahead is,
23:54you know, on schedule or
23:56even ahead of schedule. Thanks
23:58for all the faculty, you
23:59know,
24:00staff, residents, fellows who are
24:02engaging in this process,
24:04and that this is a
24:05really remarkable
24:06achievement.
24:07As you know, we are
24:08currently experiencing
24:09a big
24:11crisis,
24:12and, our co pays got,
24:14corrupted
24:15for the whole week. We
24:16couldn't get cases out. So
24:18now now everybody you know,
24:20really our staff member, faculty
24:21will have to some do
24:22the manual work. It will
24:23take some time. So it
24:25just tell you, you know,
24:26the information system for us
24:27is so critical,
24:29so important.
24:30And another only is for
24:32the, you know, work efficiency.
24:33It's really for,
24:35you know, affect the patient
24:36care and also patient safety.
24:38So we needed to really
24:40thinking,
24:40more and more and to
24:41see how we can build
24:42a much better system
24:44to really avoid this type
24:46of thing.
24:48So our reference testing program,
24:50you know, is continue. We
24:51have this preparatory testing and,
24:53divided by by,
24:55David Rimm. So, you know,
24:57it was it was a
24:58really milestone.
25:00We got it in, New
25:01York state,
25:03approval. So this is almost
25:04equivalent to FDA approval, you
25:06know, for this, breast cancer
25:08marker testing.
25:10And also, we can, you
25:11know, under the reference testing
25:12program, we expand the digital
25:15out of reach
25:16capability because this will side
25:18of the stage for for
25:19us,
25:20potentially can do the consultation
25:22using digital pathology
25:24throughout the world. So that's
25:25the really aspirational goal.
25:28Another area is that our,
25:30really,
25:31you know,
25:33pregnancy, you know, like,
25:36more pregnancy testing developed by
25:38Pei Hui. So he has,
25:39you know, his team has
25:40been building this, you know,
25:41really become, the the the
25:44one of the very few
25:45in the world to tackle
25:47this testing. So he has
25:48been actively, you know, engaging,
25:51in the,
25:52you know,
25:53clinicians
25:54as well as,
25:56you know, pathologists.
25:57So they when you know,
25:59he's the director for this
26:00center for,
26:01trophoblast
26:02disease. So another workshop is
26:04coming next year. So this
26:05is a really further promote.
26:07So this, you know, molar
26:09pregnancy testing, which is one
26:11of another very unique testing
26:14developed in our department.
26:17So at the Bridgeport of
26:19Milford, so, I, you know,
26:21you know, p p people,
26:22you know, our faculty there
26:24are really doing
26:25remarkable
26:26work. So working with, you
26:28know, you know, with your
26:30campus
26:31and, with, doctor Dasek and
26:33at all, and then we
26:34really, you know, as I
26:36mentioned, the integrated subspecialty services.
26:39Now it's a bone soft
26:40tissue,
26:41services line is primarily based
26:43at the Bridgeport on AP
26:44side. And also remember, you
26:46know, you know, Bridgeport faculty
26:49also leading the, clinical laboratory.
26:51In other words, the CP
26:53services
26:53is also at Bridgeport.
26:55So but, you know, we
26:56also, added a CP
26:59services, we also have, you
27:00know, effect you know, really
27:02working with the faculty member
27:03from Lyme Medicine, you know,
27:04this in this case, Doctor.
27:05Snyder and the new server
27:07and to also, you know,
27:08incorporate it into our pathology
27:10service there at Bridgeport,
27:12particular blood banking. So it's
27:14really doing,
27:15well. And, you know, the
27:17case of volume
27:18at Bridgeport
27:19is increasing significantly.
27:22And,
27:23you know, we mentioned this
27:25last year. So this is
27:26really under the leadership of
27:27Joanna Gibson. Somehow the her
27:30name did not show very
27:31well because he's a coward.
27:32Joanna Gibson who has a
27:33director of our patient safety
27:35and quality.
27:36So we have developed this
27:38really, really impressive quality,
27:41program.
27:42So now we have, you
27:43know, a faculty level, it's
27:45a conferences, and we have
27:47technical quality forum with also
27:49addressing patient safety. The attendance
27:51rate to getting more and
27:52more is now is a
27:53part of the CME process.
27:56And also working, Joanna and
27:58Peter Gershkovich, you know, working
28:00with,
28:01together really build up this
28:02AI assistant
28:04reported reviewer.
28:05I think as far as
28:06I know, this is probably
28:07the first example
28:09starting using AI into our
28:11pathology practice in a way.
28:13So basically, this,
28:15you know, this platform
28:17will be able to check
28:18a pathology report before the
28:20case is signed out or
28:21finalized. So this is really
28:23remarkable.
28:23You can clearly see, you
28:25know, the incorporation of the
28:27AI tools like that will
28:28further, you know, enhance
28:30our, you know, enhance the
28:32safety of the
28:34accuracy
28:35and also patient safety in
28:36terms of our reports. And
28:38the more one important thing
28:39is that certainly will promote
28:41the efficiency down the road.
28:42And also, you know, this
28:44program
28:45really, you know,
28:46ask the resident, you know,
28:48to get into this QA
28:49project. That's really, really important.
28:51We all,
28:52you know, encourage our resident
28:54and trainees to get more
28:55and more
28:57involved and develop a knowledge
28:59and a skill set in
29:00terms of quality and the
29:01patient safety. This is still
29:03very, very important area for
29:05our practice.
29:07Our residency program, so, it's
29:10really,
29:11doing well. And, we, do
29:14you particularly focus the curriculum,
29:16you know, modernization,
29:18I would say, and, you
29:20know, increase graduate student, you
29:22know, you know,
29:24our resident risk graduate
29:26responsibility
29:27and also, you know, I
29:29wasn't GME, ACGME initiative, particularly
29:32focusing on professional development.
29:34And the structure wise, we
29:35now finally
29:37created
29:37the new system for, you
29:39know, educational leader for each
29:41rotation, including both AP and
29:43CP,
29:44and also,
29:45how would the,
29:46resident to have their class
29:48representative
29:49structure. So this will allow
29:51bidirectional
29:51communication between residents and our
29:54faculty members. And the resident,
29:56you know, also achieved a
29:58pretty good, you know, scholar
30:00activity, sixteen,
30:02first, and seventeenth coauthor publications
30:04in this fiscal year.
30:07So the other, you know,
30:08program is really under doctor
30:10and,
30:11Katie Polodi, and it's it's
30:13our
30:14department,
30:15graduate program.
30:17So this program, right, you
30:18know, it used to be
30:19the experimental pathology program. So
30:21we renamed it that two
30:23years ago. We call pathology
30:24and the molecular medicine PMN.
30:27So right now we have
30:28the largest of the class
30:29ever, you know, in our
30:30program. We have thirty six
30:31students.
30:32And the only, you know,
30:34by last two years, we
30:35have twenty students coming
30:38in last two years. So
30:39it's really remarkable
30:40and it just, you know,
30:42shows, you know, attract you
30:44know, that means our research
30:45and the training really attract
30:47the potential trainees. And we
30:49also reflect
30:50our, you know, faculty members
30:52reach research
30:53caliber, and we'll be able
30:55to support and attract a
30:57new graduate
30:58student. And,
30:59in in Miro with residency
31:01program, we also developed the,
31:03you know,
31:04pathology really,
31:06chief graduate student in the
31:07program. We have two chiefs.
31:09Just as I said, the
31:10Miro, our residency program is
31:12James Elliott and Shannon Silver.
31:14They are doing fantastic job.
31:16So many of our trainees
31:18is on fellowships. You can
31:20see eighteen out of the
31:21thirty six are different fellowship
31:23including
31:24an age and also foundations
31:26fellowship. This and,
31:29the you know, each year,
31:30there will be one renderer,
31:32you know,
31:33speakers invited by our graduate
31:35students. So this past year,
31:37we have really
31:39the most of
31:40basically, the father of the
31:42KRAS inhibitors is Frank McCormick
31:44came to give a fantastic
31:46lecture.
31:47And, also the we have
31:49the research retreat. The research
31:51retreat is really, really
31:53pipe and, you know,
31:55organized by the graduate program,
31:57particularly the two chief residents
31:59and along with doctor Garrickati's.
32:01So this year's retreat attendance
32:03reached the hundred twenty five
32:04attendance. It's really remarkable.
32:07So along that line, you
32:09know, our graduate student really
32:11thanks for their participation for
32:12our Yale pathology day. So
32:14I'm going to, you know,
32:15we have this will be
32:16our third year of Yale
32:17pathology day. They are really
32:19the active,
32:20you know, participant participants.
32:24And in terms of the
32:25training program,
32:26I would just say, you
32:27know, really, thanks for doctor
32:29Schopper and doctor Katz. So
32:31they pioneered to put this
32:33t thirty two,
32:35training,
32:36for diagnostic pathology together.
32:38Really got a fundable score.
32:40You know, if in a
32:41normal NH year, the grant
32:43probably would be funded.
32:44As you know, the chaos
32:45added, you know, added the
32:47NH, so, you know, they
32:48resubmitted the grant. We hope
32:50that this will be funded.
32:51So this will be the
32:52fir first such training grant
32:54in our department.
32:55And and then the others,
32:56you know, the cancer biology
32:58training grant renewal is under
33:00Yan,
33:01and,
33:02David Stern. So it got
33:03submitted for continuation renewal.
33:06And, also, they sort of,
33:07you know, the and myself
33:09put together is r twenty
33:11five. So we got this
33:12funding for funding
33:13for the summer,
33:15scholar program. This is really
33:17focusing on high school student.
33:19You know, this is another
33:20training program. Again, I just
33:22mentioned that we this will
33:23be a we have done,
33:25really, you know, pathology
33:27Yale Pathology Day, you know,
33:29aiming, you know, reaching to
33:31the high school students, and
33:32it's getting more, very popular.
33:34So we're going to have
33:35another one this Saturday. So
33:37now all of this really,
33:38you know, organized and allied
33:40by, Gina.
33:42It's really a special thanks
33:43to Gina for her contribution,
33:46you know, helping to put
33:47a grant together and organize
33:49all these, these programs.
33:52And, also, our facade, one
33:53thing in particular I wanna
33:54highlight is really we, our
33:56department,
33:57our faculty really revived or
33:59reenergized
34:00that
34:01they Connecticut Society for Pathologists.
34:04As you know, health care
34:05tended to be local,
34:06you know, so that's why
34:07we have the national organization.
34:09Our many faculty members are
34:10really engaged at the national
34:12level, But at the same
34:13time, we really needed to
34:15have a local representation or
34:16local voice, which is Connecticut
34:18Pathologist Society.
34:20And doctor Minores and doctor
34:21Zhang, you know, doctor Danra,
34:25doctor Klimistra,
34:26and,
34:27you know, Sumi Thomas, they
34:29are heavily
34:30engaged with the society.
34:32So there there will be
34:33another annual meeting in the
34:35January,
34:36in February next year.
34:39So the thing is I
34:40haven't because of time wise,
34:41I won't be able to
34:42acknowledge all our faculties achievement
34:45and all that, but we
34:46do have a really terrific
34:48communication team in, you know,
34:50the pioneer,
34:51led by Terry here, you
34:53know. So this is our
34:55primary communication part. It's a
34:56pathology lighter. It's a monthly.
34:58So this is just the
34:59our first recent the most
35:01recent one in October.
35:02So please, this will be
35:03the one you also share
35:05your story and make your
35:06announcement.
35:13News to share, some recognition
35:14you'll receive, some award you'll
35:16receive, but you have to
35:17let us know. So we
35:18really acknowledge
35:19our faculty, staff member,
35:21the flat major graduate student
35:22and the postdoc residence. You
35:24please feel free to reach
35:25out to to Terry. So
35:26this is a really we
35:27need a more communication, and
35:29then we need to get
35:30together
35:31to really celebrate,
35:32you know, our collective achievement.
35:35So in the next few
35:37minutes, I'll talk about our
35:38financial performance.
35:40So we are
35:41still doing fine.
35:44You know, our total revenue
35:45is still increasing.
35:47But also although you see
35:49the physical twenty four, you
35:50know, we have, you know,
35:51we have ninety one million
35:52dollars. You find physical twenty
35:53five. We have eighty four
35:55million dollars. This is a
35:56accounting issue because we have
35:58this new funds flow. So
36:00there are certain, the portion
36:02from the new New Haven,
36:03the purchase services now is
36:05real, you know, is reassigned
36:07at the Yale Medicine. At
36:08the same time, they will
36:09pull our expense up. So
36:11in the, in, in, if
36:13we continue the old system
36:15and the I extra revenue
36:16is around probably ninety three
36:18million dollars. So that's usually
36:20it it doesn't matter. At
36:21the end of the day,
36:22you know, it's if they
36:23take away
36:24the
36:25the revenue side, at the
36:26same time, we
36:28recover your expenses at the
36:30end of its margin. Right?
36:31Now we're talking about that
36:32the margin is more important
36:33than anything else. So what
36:35what's our margin?
36:36So our revenue, I'd say,
36:38is eighty four million dollars.
36:40Our expense is eighty two
36:41million dollars. So we got
36:43a margin of one point
36:44three million dollars this year.
36:45But with everything on our
36:47cardholder, we still make some
36:48money, so a little bit.
36:49But we would like to
36:50see more, but I have
36:52to say this is the
36:53the lowest things I got
36:54here, and the the margin
36:56is one point three. But
36:57it was challenging year for
36:58physical twenty five, but I
37:00I I you know, we
37:01needed to tell me which
37:03kind of opportunity that's with
37:05what we can talk about,
37:06you know, in the next
37:06few minutes
37:08minutes. So our clinical
37:09work RVU, as you know,
37:11this RVU is the really,
37:13they
37:14cross all medicine. It's not
37:16just pathology. What a medicine
37:18in in in in medicine,
37:21what you are getting to
37:22pay down now is based
37:23on the RVU. Right? So
37:24all the reimbursement is based
37:25on RVU. So we have
37:26two hundred seventy five thousand
37:28RVU, say, for our department.
37:30So this is really foundation.
37:31It's really gradually increasing every
37:33year. So this is really,
37:35just to acknowledge our clinical
37:37faculty's really hard work and
37:38then their effort.
37:40So right now for that,
37:41you know, using benchmark, the
37:43national benchmark for
37:44an atomic pathology
37:46is about six three six
37:47thousand three hundred RU per
37:49clean VVT. So with this
37:51RU number we have, we
37:53have, you know, achieved. So
37:54it's a part of forty
37:55three full time clean VVT.
37:57We are doing much better
37:59than we are doing well.
38:00In other words,
38:01department collectively,
38:03we are above our benchmark.
38:05So that's how, you know,
38:06really, you know, our faculty
38:08man probably will feel,
38:10you know,
38:12work work you know, lots
38:12of work.
38:14It's really feel,
38:15you know, the the, you
38:17know, the effort to put
38:18into it is tremendous. But
38:20the reason for that is
38:21as a department
38:23to get, you know, as
38:24a department as a whole,
38:26so we are above the
38:27national benchmark, you know, in
38:28terms of per Canadian FTE
38:30RVA. So this is always
38:31good because this will allow
38:33us to deliver
38:34margin. Margin. Look. So what
38:36happened that you see because
38:37our hard work is over
38:38the benchmark, our clinical margin
38:41is actually close to nine
38:42percent. Alright? So after of
38:44the forty thousand, we you
38:45know, those are significant
38:47dollars. This is our clinical
38:48margin.
38:49But, our research margin is
38:50negative, but that's always the
38:52case. You also the case.
38:54But the thing is, you
38:55we you know, we as
38:56a department together, we have
38:58a margin,
39:00one point three million dollars.
39:02But if you break down
39:03the mission, the educational margin
39:05is really
39:06I mean, education, you'll never
39:07make money. So that's how
39:09why it's always deficit. But
39:11the question is always how
39:12we could get the deficit
39:14smaller and smaller and get
39:15the positive margin higher and
39:16higher. That's how you make
39:18the eventual margin, you know,
39:20one point three. As I
39:20said, our
39:23goal is really to have
39:24a margin somewhere around between
39:26three to four million dollars.
39:28Then we can do a
39:28lot of things together because
39:30those are actually the past
39:31several years. We always have
39:32up around three or four
39:33million dollars margin together. So
39:35I think, those are the
39:37the thing,
39:38one that just to share
39:39with you. I mean, overall,
39:41we are doing fine. But
39:42I think of it thanks
39:43to everybody's effort. We are
39:46one of the top department
39:47in the school
39:48have the highest number of,
39:50cache on hand in in
39:52hand. In other words, we
39:53have pretty good cash
39:55reserve, you know, in our
39:56department. So in other words
39:58to sustain our mission.
40:01So the also the space
40:04renovation,
40:05you
40:06know, finally, I think it's
40:07particularly related to deep out
40:09there, you know, and also
40:11a kind that just came
40:12here in not no no
40:13no permanent home yet. So
40:14I think it's a there
40:16is a light under at
40:17the end of the tunnel,
40:18you know, it's really, the
40:21completion date is around April
40:23twenty twenty six, you know.
40:24Okay. So fingers crossed. Hopefully,
40:26nothing will happen unexpectedly.
40:29And also the the
40:31the Lauderhill,
40:32first floor,
40:34will start right after that
40:36project is in the summer
40:37of twenty twenty six. The
40:38design already
40:40pretty much completed.
40:41So it's a school already
40:42approved the funding so that
40:44the other renovation will come
40:45in. And then after that,
40:46you know, the the BMF
40:48three, you know, that will
40:49be in on the planning
40:50stage. So that's probably what
40:52after with the Lauderhill,
40:55first floor is done, then
40:56we can do we cannot
40:57do all of them together
40:58anyway because we don't wanna
41:00cause too much, you know,
41:01too,
41:02too many disruptions. That's the
41:04another issue we have to
41:05do it, you know, sequentially.
41:08Alright. So the some of
41:10the key
41:11task is in physical twenty
41:13six. We are in the
41:14physical twenty six now. It's,
41:15you know, back to the
41:17to June.
41:18Digital pathology AI, that's really
41:20the top area. We have
41:21to really push ahead and
41:23try try everything possible.
41:25And then team science grant
41:27and the training grant is
41:28still our priority in the
41:29department. We really wanted to
41:31see how we can promote
41:32the the team science.
41:34Optimizing clinical operation is still
41:36the priority and,
41:38implementing
41:39AP beaker, so stay.
41:41Growth philanthropy,
41:43we always talk about that.
41:44It's not easy, but we
41:45have to get somewhere. So,
41:47this year, we would like
41:48to do some annual, fundraising,
41:51this year and align alignment
41:53with the institutional priority. As
41:55I mentioned today, particularly, I
41:57shared with the school's strategic
41:58planning. So with client, you
42:00know, we are doing well.
42:01So we aligned with the
42:02school and with the house
42:03data very well.
42:05So, always pursue opportunities for
42:07growth and innovation. So I
42:08can just highlight a few
42:10areas,
42:11see, you know,
42:12where we can grow after
42:14this. Challenges,
42:15no question. Because this is
42:17a really,
42:19not good not a easy
42:20time
42:21for for for almost for
42:23all of us. Right? And
42:24the the federal grant funding
42:26is still,
42:27uncertain, but it seems the
42:28government at least opened it
42:30today. So many of the
42:31study sections now resume. You
42:33know? I think so one,
42:34the migrant that they they
42:35delayed, but now they tell
42:37me one month later, they
42:38will review that grant. So
42:40I think it's like, all
42:42of us experienced this. The
42:43capital investment
42:45is really, really hard right
42:46now from both of the
42:47school side and also the
42:49health system side. You know,
42:50the the health system financially
42:52is challenging. So that's how
42:54many of the
42:55capital equipment for for instance,
42:58our digital pathology will need
43:00a lot of capital equipment
43:01that we we cannot get
43:04capital,
43:05money from the hospital.
43:07So that's why with doctor
43:08Tisi, with doctor Levi, we've
43:10been really, really creative trying
43:12to work with wonders.
43:14I think we kinda crafted
43:15something, you know, something,
43:17hopefully,
43:18almost at the last stage
43:19of sign of the PO.
43:21We'll be able to get
43:22all the scanners, the digital
43:23pathology platform without the hospital
43:26putting capital fund. So this
43:27is a really
43:28innovative way to get things
43:30done.
43:31Hopefully, that this will happen.
43:33And then we as I
43:34said, you know,
43:35the really margin generation to
43:37support our mission into for
43:39the whole department as a
43:40whole is a clinical margin.
43:42Because we are now the
43:42basic science department, we do
43:44not receive a deans subsidized.
43:46Like a basic science department,
43:47we do not receive anything
43:49like that. So it's our
43:50entire
43:51operation is based on the
43:53clinical margins we generate. Alright?
43:55So this is how we
43:56really wanted to see how
43:58we can,
43:59you know, work better and
44:01to achieve the more clinical
44:02margin. As I mentioned, it's
44:04a new few new, like
44:06a new opportunity area we
44:07all need to think about,
44:08of course, you know, new
44:09cutting edge science to pursue,
44:10you know, in the department
44:11that this is really for
44:13our science focus of faculty,
44:15thinking about some
44:16areas, you know, we'll be
44:18able
44:19to, you know, to grow,
44:21you know, to to fruition.
44:23Because as I mentioned, to
44:24our faculty all the time,
44:25the department
44:26wants to make investment
44:29in terms of shared
44:31equipment, some even, you know,
44:33hiring particular people,
44:35but we really need ideas
44:37from our, you know, faculty
44:38to see what would be
44:40the platform
44:41type of science,
44:42enable more investigator in the
44:44department to do well in
44:46the next few years. So
44:47really, if you have an
44:49ideas, any initiative,
44:51just bring that forward, and
44:52then we will, I mean,
44:54we'll find a way to,
44:55you know, to invest, and
44:57we'll find a way to,
44:58you know, to to see
44:59if we can grow.
45:01As I said, we it's
45:03not like we do not
45:04have found that we do
45:05not have a will, you
45:06know, willingness
45:07to to invest. So we
45:09we actually wanted to fund
45:10this. We wanted to work
45:12with you.
45:13All what we have, at
45:14least I myself, wanted to
45:16have is more new ideas
45:17from all of you. Right?
45:19The other is a therapeutic
45:20pathology researcher. We really need
45:22need to promote that well
45:24and then grow that area
45:25because this is really from
45:27the industry
45:28perspective.
45:29This is a heavily, heavily
45:31invested area. Certainly, it's very
45:34it's a high impact area.
45:36Which patient wound the wanted
45:37to have some new therapy,
45:38right? We really needed to
45:39do more in the therapeutic
45:41pathology area.
45:42And then the others that
45:43we needed to think about
45:44our pathology practice.
45:46So pathology has always been
45:48considered as a hospital based
45:50practice,
45:51but this concept that needs
45:53to be changed, right? We
45:54need to also think about
45:56ambulatory pathology service.
45:58So right now, as you
45:59know, in medicine in general
46:01is go to ambulatory,
46:03you know, patient side, patient
46:05side services.
46:06So that's why we're going
46:07to pursue this first one
46:09is go to,
46:11you know, the, shoreline
46:13ambulatory surgical center. So what
46:15we want us to do
46:15is our pathology will provide
46:17extra frozen section coverage on
46:19the pathology service on-site
46:21at the,
46:22you know, shoreline,
46:24sir you know, surgical center.
46:25Those are the ambulatory sites.
46:27So we needed to do
46:28more upon, you know, to
46:29bring our service to patients
46:32patients by our clinical side.
46:34So those are the really
46:35important area we have to
46:36grow.
46:37And then, the others is
46:39really, you know, pathology always
46:41considers
46:42a do not contact patient,
46:44but we do have opportunity,
46:46particular cytopathologists.
46:47You know, we have the
46:48face patient facing diagnostic practice,
46:51which is if any clinic.
46:52So we're in the process
46:53right now working with our
46:54colleagues in radiology,
46:56trying to build our, you
46:58know, if any clinic. So
46:59this will really,
47:01another
47:02area to think about,
47:04to grow.
47:05So at that end, I
47:06will just
47:08find a way, as I
47:09said, to support our mission,
47:11we always try and, you
47:13know, I wanna
47:14just reuse these slides again,
47:16just let everybody know also
47:18how we gather our fund,
47:19right, to support our department.
47:21So the one is, you
47:23know, our clinical payment. Right
47:24now, we are RVU web
47:26model. So so it's our
47:27real payment is good. And
47:28then some medical director say
47:30purchase services.
47:31Those are really difficult negotiation.
47:34Right? I mean, you know,
47:35you have to spend hours,
47:37days, and months is negotiate
47:38with hospital trying to gather
47:40those purchase services, medical director.
47:42Well, it's it's not easy.
47:44Alright? Particularly
47:45when the other side has
47:46a lot of financial challenges.
47:48So those are uncontrollable.
47:50To and now the other
47:52academic support, those are really
47:54right now, our department, the
47:55formula with the dean
47:57is eighty percent eighty to
47:59twenty. In other words, if
48:00we recruit a faculty member,
48:02research research faculty member, so
48:04our department that we have
48:06to be responsible eighty percent
48:07of the startup package, the
48:09dean would respond for twenty
48:10percent. It used to be
48:12fifty to fifty in the
48:13old system, you know, because,
48:15the the you know, this
48:16is the base
48:17on the the cash flow
48:19the department has. We are
48:20sort of a it's good
48:21problem to have. We have
48:22higher cash flow. So it's
48:24a good school side. So
48:25you are responsible eighty percent
48:26where respond twenty. That's what
48:28the from school. This is
48:29a alright. So the one
48:31really under our control, I
48:32will say, grant and the
48:33contracts. In other words, you
48:35know, we have we need
48:36to gather grants. We need
48:37to gather contract, particular working
48:38with biotech company. You name
48:40it. You know, the we
48:41have, you know, particular, like,
48:43you know, we have two
48:44two two faculty member doing
48:46really well. It's David Raymond,
48:47you know, Curtis Shopper. They
48:49have a lot of contract
48:50with a biotech company. So
48:52those are under our control.
48:53The others are out of
48:54reach reference testing As you
48:56know, outreach out of our
48:57outreach
48:58program really is the one
49:00deliver
49:01significant margin to us. So
49:03without that,
49:04we are not aware we
49:05are today. Right? So this
49:06is the area we wanted
49:07to grow. It's under our
49:08control. Endowment that gave those
49:10are philanthropy. We wanted to
49:12grow. It's under our control.
49:13It's not easy. But I
49:14think as we all know,
49:16but but we have to
49:17make an effort. So the
49:19other way I'll highlight the
49:20royalty
49:21because we never had this
49:23system. You know, department dot
49:24a u doesn't receive any
49:26royalty payment, you know, all
49:28the time. Two years ago,
49:29they changed it. So now
49:30there will be department that
49:31will actually receive thirty percent
49:33of royalty for any invention
49:35coming from our department
49:37faculty. Alright. So this is
49:39why it's so important. And
49:41now I want to encourage
49:42faculty to think about, you
49:43know, how to translate your
49:45research into
49:46license. Somebody, either you spin
49:49off a company yourself or
49:50your license to somebody and
49:52those are licensing fee right
49:53now, the department will kinda
49:55actually keep a thirty percent.
49:56So this will be another
49:58potential source of revenue to
50:00coming in. I also use
50:01the example. I know, you
50:03know, MGH,
50:05their annual royalty is three
50:06million dollars.
50:08Think about that. Right? Because
50:09they if we have something
50:11like that, that would be
50:12really significant to improve our
50:14you know, really enhance our
50:16ability to invest on those
50:18super power program.
50:20Alright. Keep take keep, you
50:22know, you know, takeaway
50:24point. Our department is strong.
50:26Thanks to all of you
50:27for your dedication contribution.
50:29And our faculty, trainees, and
50:31staff, they are all engaging,
50:32dedicated. You know, thank you
50:33to all of you.
50:35Our strategy plan is now
50:36is really aligned with the
50:38schools and it's we are
50:39it's working, either achieving,
50:41you know, our success.
50:44One more thing, I've I
50:46think I actually I mean
50:47it. So this is what
50:48I really like, you know,
50:49the way you think about
50:50that. So in time of
50:52uncertainty and challenge, creativity
50:54becomes essential.
50:56It is an opportunity
50:57for all of us to
50:59rethink,
50:59adapt, and discover new way
51:01of doing things. We cannot
51:03say, oh, we used to
51:04do it all the time.
51:05This isn't certainly not the
51:07time. We're capable of doing
51:08what we have been doing
51:09for years. And this is
51:11really require all of us
51:13thinking about how to
51:15do things differently, you know,
51:17to really face the challenge
51:19and to to
51:20to be
51:21successful. So that's the end
51:23of my,
51:24presentation. Now it's open for
51:26question, and I hope, you
51:27know, you will have a
51:28lot of comments and questions,
51:30and then then we can
51:31talk. Thank you very much.
51:40Questions?
51:41Oh, yeah. You You mentioned
51:43about launch speed? Yeah. I
51:45was curious about, like, some
51:46of the events or some
51:47of the ideas that you
51:48somehow
51:49have, maybe some some some
51:51thought on that. Yeah. Okay.
51:53Philanthropy can have multiple different
51:56form. Right? I mean,
51:58you know, one is, you
51:58know, research area you are
52:00working,
52:01for example, particular disease
52:03specific area, for example, you're
52:04working on Alzheimer's disease, Parkinson's
52:07disease, you know, those you
52:08know, the people who who
52:10have
52:11resources,
52:12they have family member, friends
52:13that they have that pension,
52:14you really they will start
52:16with interest and donate to
52:17support that program. That's one
52:19way to do research.
52:21And then then the other,
52:22you know, where in the
52:23medical field, so there's this
52:26really big philanthropist
52:28called the grateful patients,
52:31program. You know, basically, the
52:32patient got the treatment for
52:33with whatever, lung cancer, breast
52:35cancer. They feel very good
52:37after that, and then they
52:37don't they donate it to
52:39the program.
52:40Also, they don't go to
52:41the nursing, donate to but,
52:43unfortunately, we are not in
52:45that category,
52:47you know, you know, because
52:48we don't direct that they're
52:49taking care of patient or
52:50treating patient for pathology.
52:52However,
52:53the thing is that's why
52:54I'm saying some of the
52:55time I use either the
52:56sync differently, creatively.
52:59However, what I'm saying is
53:01doctor Harry Sanchez and, you
53:03know,
53:04Mark Mark doctor Marcelo,
53:06you know, Marcelo,
53:08they develop, you know, the
53:10rapid autopsy program. So that
53:12basically the donor, you know,
53:13patient the legacy donor program.
53:15And that's when the patient
53:16will have wish after they
53:18are passing, they want to
53:19donate their body, you know,
53:20to,
53:21you know, for their tissues
53:23to be used for research.
53:24So we had that program
53:26running.
53:27But to our surprise, we
53:28never thought about this will
53:30be a philanthropy in a
53:31way. However,
53:33there are patients,
53:34families, they donate money to
53:37this crime. So in other
53:38words, in our department right
53:40now, really, the active
53:43donation account
53:44is this rapid update. Like
53:46I say, donor program. You
53:47see, you see, you know,
53:49I would never have thought
53:50about that myself,
53:52but I think this is
53:53just tell you there are
53:54multiple different ways. But the
53:55bottom line is that you
53:56have to do things, you
53:58know, well. Because we even
54:00for this don't legacy donor
54:02product, we even have the
54:03board members
54:05of the health system.
54:06They inquire how we can
54:08help them. They are family
54:09members. They have that. So
54:11so this is certainly opportunity.
54:14So you will think, okay,
54:15people won't do that. People
54:16actually
54:17trying
54:18to really have their last
54:20gift to the world, but
54:22they just wanna make sure
54:23that
54:24somebody will make it happen.
54:26Certainly, that this will be
54:27our area.
54:29You know, this will be
54:30our expertise. We'll make it
54:31happen. I think this is
54:32the one.
54:33Alright? So so it can
54:34be multiple different form, just,
54:36you know, many ways. Yeah.
54:37Imagine, you know, I know
54:38you you you in your
54:39graduate school, there are some
54:41people may feel they wanted
54:42the next generation of scientists.
54:44They may have passion to
54:46donate for postdocs or graduate
54:48students. That's
54:49a way to think about
54:50it. Thanks, Luis.
54:52Rob?
54:53I think Joanna. Oh, Joanna.
55:02Yeah. Yeah. I can repeat
55:03that question. You know, any
55:04plan to renovate the EP
55:07two area?
55:08Well,
55:09so this one, I, you
55:11know, we
55:13all know there's almost impossible
55:16to have any renovation in
55:17the e p two area.
55:19That space cannot be renovated
55:21in other
55:23so we are actually pursuing
55:25other opportunity
55:26to see if we can
55:27relocate
55:28some of our
55:29our,
55:30functions to other places.
55:32One area is actually with
55:34working with the health system,
55:37facility leadership and also lab
55:39leadership.
55:39We're actually
55:41actively looking at the Park
55:43Street where laboratory medicine is
55:45to see for opportunity any
55:47opportunity there to help, you
55:48know, some functionality
55:49go there. But as you
55:51as you know, you I
55:52don't know how many will
55:53you go to the the,
55:56light medicine area. You know,
55:57the the the the Park
55:58Street is beautiful. They build
56:00the, you know, facility.
56:02But the thing is, you
56:03see, you have their love
56:04of empty space. You get
56:06into it. So now it's
56:07you will see the floor
56:09from top to the fifth
56:10floor. It's the the Atrium
56:11area entirely open. It's nice.
56:13I mean, like a concert
56:15hall, right? Yeah. It concert
56:16hall is nice. But the
56:17thing that architects are actually
56:19thinking about to make the
56:21top of fourth
56:22fifth fourth floor to cut
56:25that out, extend a floor
56:27on the fourth and fifths,
56:29make the atrium area smaller.
56:31So that will actually I
56:33mean, we we told them
56:34all we need is if
56:36they can extend the two
56:37floor, fourth floors, and the
56:39fifth floor,
56:40our entire AP lab can
56:42be located, relocated there. There
56:43are certainly a lot of
56:44advantage
56:45to have our AP lab
56:48colocalized
56:49with CP lab. No question
56:51about that. So I know
56:52it's a disappointment that, you
56:53know, the
56:55the constant leaking, you know,
56:56leakage or the crowding space.
57:00This is one of the
57:01thing I feel sorry for,
57:03you know, cannot really resolve
57:06this issue.
57:08It was in my offer
57:10letter.
57:11So they will help, run
57:12away the space.
57:14Thank you.
57:16Chen, I just wanna ask,
57:17could you continue to, it's
57:19Marie. Just if you can
57:20continue to repeat the questions
57:22for those of us on
57:23Zoom. Okay. Got it. Thank
57:24you so much.
57:26Yeah.
57:27So any other question?
57:32There's
57:34a
57:35chat.
57:40I don't
57:42I don't see here.
57:45Can anybody
57:46I mean, anybody, you know,
57:47ask a chat question. Can
57:49you just unmute and ask
57:50the question, please? But I
57:52cannot
57:53find the chat box here
57:55on my screen.
57:56Yes.
57:58Image. Two years ago, the
57:59university
58:01reoriented
58:04this first royalties.
58:06Birth before royalties.
58:10But,
58:11we had a drug in
58:12phase three. It's gonna be
58:14done in two months. Mhmm.
58:16And it, you know, was
58:17acquired by a company.
58:19It's a big company. It's
58:20taking ourselves with every information.
58:22It's gonna be improved.
58:24This is a project that,
58:25you know,
58:26I ran out of money.
58:27The party gave me money
58:29to keep it going,
58:30and it turned out to
58:31be successful.
58:33And it's been eight years.
58:34I mean, you know Is
58:35that and do an eight
58:37years different than you also
58:38say.
58:39You know,
58:40Can you go to the
58:41dean? Is it is the
58:43dean a nice lady? Can
58:44you go to her and
58:45say,
58:46would you consider, you know,
58:48back in this? You know,
58:49for
58:50I mean, otherwise, we're waiting
58:52another
58:54decade. Yeah. So I I
58:56mean, I don't know. So
58:56for example, been to so
58:58the question is from,
59:00Demetrius asking about the royalty
59:03distribution. You know, he certainly
59:05has a really successful,
59:07drug development coming from other
59:09department.
59:10Now now his question is
59:12to see how whether or
59:13not that we can get
59:14us some prepayment
59:15from the dean, from the
59:17school. Yes.
59:18You do right. Right. So
59:19to get that so we
59:21you know, the answer is
59:22we'll certainly follow that very
59:24closely. Right? That's the privilege
59:26the closest one we can,
59:28you know, get some royalty
59:30sharing.
59:31But again, we don't know
59:33how it work. It only
59:34put it in place two
59:35years ago. Right? Universe only
59:37reoriented
59:37the relative because we never
59:39had that before. Right, John?
59:40You've been a
59:42you try they'll never had
59:43that before. We don't the
59:44department doesn't have any,
59:46sharing of the the the
59:48the royalties, but now we
59:49do. So so okay. Wilfa,
59:51thanks for continue to do
59:52what hopefully, good luck with
59:54the phase three trial, but
59:55I think, we needed to
59:57do more of that.
59:59Okay.
60:00Chen, can I ask a
01:00:01question on Zoom? Yes, please.
01:00:03I don't know if you
01:00:04can hear me on I
01:00:05hear you well. Enough. Okay.
01:00:06I don't wanna be too
01:00:07loud either. So it was
01:00:09very encouraging to see that
01:00:11overall as a department,
01:00:13the RVUs,
01:00:15per person are are on
01:00:17track. But I just wanted
01:00:18to ask for more clarification
01:00:20because, you know, we had
01:00:21a a good robust discussion
01:00:23on the GI team,
01:00:25and I'm sure they're all
01:00:26asking themselves the same question,
01:00:28that, that it looks like
01:00:30there'll be some changes
01:00:32to the benchmarks depending on
01:00:34subspecialty
01:00:35because
01:00:36we, you know, the average
01:00:37number there was about six
01:00:38thousand three
01:00:39hundred,
01:00:41but based on yesterday,
01:00:42we know that
01:00:43we're we're moving towards a
01:00:45higher benchmark and being consolidating
01:00:47our GI services. So I
01:00:49do can you share more
01:00:50about
01:00:51we're good, but still with
01:00:52there there's some
01:00:54different benchmarks, or or what
01:00:55would you how would you
01:00:56explain that?
01:00:58Yeah. So I think, Marie,
01:00:59this is a quest question
01:01:01I think,
01:01:03every chair in the country
01:01:04probably was struggling with that.
01:01:06Right? Because of the in
01:01:07other words, all our clinical
01:01:09faculty, we all have a
01:01:10different,
01:01:11subspecialty.
01:01:12We do different things. But
01:01:14the the RU,
01:01:16I mean, we we always
01:01:17can complain. It's good. It's
01:01:19fair and not fair, but
01:01:20I think that's how they
01:01:22do it.
01:01:23You know, for example, we
01:01:25all know is one GI
01:01:27biopsy.
01:01:29One biopsy is
01:01:31point seven
01:01:32RU. You know, you read
01:01:33the one eighty eight three
01:01:34zero five is a point
01:01:35seven,
01:01:36and then you read one
01:01:37liver is only one point
01:01:39two.
01:01:40You see the time you
01:01:41put a reading a liver
01:01:42biopsy versus a tubular adenoma
01:01:45is tremendous different. However, that's
01:01:47how they award that they
01:01:48relate our view. If you
01:01:50just use Medicare payment, basically,
01:01:52one RU is equivalent equivalent
01:01:54of about fifty dollars You
01:01:56just do the math. I
01:01:57mean, commercial rate is a
01:01:58high a lot higher,
01:02:00depending on contract. It's basically
01:02:01the one hour view is
01:02:02fifty dollars. Right? So I
01:02:04think
01:02:06I'm as I said, you
01:02:07know, because we have a
01:02:08different sub spectrum, we have
01:02:09a complete subspecialty
01:02:11service. Within our department,
01:02:14GI has the highest highest
01:02:16RVU. No question. All our
01:02:17faculty, they are fake, you
01:02:19know, the RVU close to
01:02:20eight thousand, nine thousand,
01:02:22totally above the
01:02:25the benchmark for the AP.
01:02:26But at the same time,
01:02:27you have other specialty, you
01:02:29know, we are not even
01:02:30close to the six thousand
01:02:32benchmark.
01:02:33But then in this scenario,
01:02:34we have to consider department
01:02:36as a whole. So that's
01:02:37why we never wanted to
01:02:38individualize
01:02:40each faculty member.
01:02:41So how many hours you
01:02:43needed to deliver because we
01:02:44cannot
01:02:45turn the department into a
01:02:47GI only practice
01:02:49or some other high hour
01:02:51view. For example, the other
01:02:52one, if
01:02:53we we don't have a
01:02:53dermatopathology
01:02:54in our department. If we
01:02:56if we did, the the
01:02:58mental pathology will have
01:03:00ten or twelve thousand RUs.
01:03:01That's what their
01:03:04their practice. Because if they
01:03:05have this,
01:03:06you know, like a biopsy
01:03:08scan, they have a five.
01:03:10Each biopsy scan is still
01:03:12zero point seven RU.
01:03:13It's just,
01:03:15you know, they can you
01:03:16can really read that for
01:03:18ten seconds, you know, that
01:03:19but at the same time,
01:03:20you you have the RU.
01:03:21So I think, Marie, I
01:03:22think, I I as I
01:03:23said, it's it's a challenging
01:03:24area, but at the same
01:03:26time,
01:03:27we can also cannot ignore,
01:03:30say, oh, you have nine
01:03:32thousand
01:03:32ARIO. You you just did
01:03:34nine thousand ARIO.
01:03:36You know, leeways it. But
01:03:38I think that that's another
01:03:39way we need to think
01:03:40about
01:03:41how we can I mean,
01:03:42RU we have is really
01:03:44work there? There's no question
01:03:45about it. If we have
01:03:46a nine thousand RU, you
01:03:47think about how many patients
01:03:49you have seen each year.
01:03:50Right? So that's actually, you
01:03:51know, our g f equity
01:03:53can have eight and nine
01:03:54thousand RUs, you know, per
01:03:55year. So I I
01:03:58don't have a definitive
01:04:00answer to this, or I
01:04:02do not have a solution.
01:04:03I think,
01:04:04I do not believe any
01:04:06other
01:04:07chairs that we have really
01:04:09the perfect solution. It's somehow
01:04:11we all try to find
01:04:13the best practice.
01:04:14But the overall thing is,
01:04:16I think we have to
01:04:17single department as a whole.
01:04:19At the same time, acknowledge
01:04:20people who really making contribution
01:04:23to the department financial bottom
01:04:25line. No question about that
01:04:25because that's how we gotta
01:04:27pay it. The high Oh,
01:04:28sure. I'm sorry. I actually
01:04:29what that that wasn't the
01:04:31I'm sorry. I was trying
01:04:32to ask a different question
01:04:33and I want to be
01:04:35clear. I'm not
01:04:36I am
01:04:38fully
01:04:39in agreement with having all
01:04:41the subspecialties,
01:04:43they're all needed no matter
01:04:44what the RVU is. That
01:04:45was not it. But we'll
01:04:47talk later. It was just
01:04:48Yeah. We talked We had
01:04:49a different conversation yesterday that
01:04:51that Yeah. We Now it's
01:04:53nice it's nice that overall,
01:04:54it sounds like we're doing
01:04:55very well. So that's that's
01:04:58everybody. We are, you know,
01:04:59collectively, we're doing well. That's,
01:05:01I think, more important. Other
01:05:03than with lots of other
01:05:04things, we we yeah. We
01:05:05can have more conversation.
01:05:07The thing is
01:05:08alright. Any
01:05:09Can I can I ask
01:05:11a question? Yeah. Please. I
01:05:12mean, okay. Hey.
01:05:14You know, how does the
01:05:15medical school leadership
01:05:17and the hospital leadership view
01:05:19anatomic pathology? Can you tell
01:05:21us a little bit about
01:05:22that? I mean, these are
01:05:24the things that we do,
01:05:25and it's encouraging to hear
01:05:27that we're doing well. But
01:05:29what is their view of
01:05:30us? What is their perception?
01:05:33I mean, they did not
01:05:34give us any award. I
01:05:36mean, we were I I
01:05:37I
01:05:38what I'm saying but they
01:05:40we are doing well because
01:05:41they never criticize us. They
01:05:43always think that we are
01:05:44great. You know, we are
01:05:45doing well. We are very
01:05:46essential. You'll have certain line
01:05:47at home facility is essential,
01:05:49particularly for cancer center. They
01:05:51know our value. Without us,
01:05:52they cannot practice cancer care.
01:05:56I mean, I I think
01:05:57it's good, but at the
01:05:58same time, they that's probably
01:06:00why they leave us alone.
01:06:02But I think sometimes
01:06:04this will be the best,
01:06:06I would say, recognition if
01:06:07somebody leave you alone.
01:06:09Right? That, you so in
01:06:11a way, you know, for
01:06:12our recruitment I mean, also,
01:06:14we go through the same
01:06:15loop, but our scrutiny
01:06:17is never being as hard
01:06:18as some of the deficit
01:06:19department, for example. Right? If
01:06:21you're basic science department, you
01:06:22say, oh, I wanna put
01:06:23a for the faculty member,
01:06:24good luck. You know, and
01:06:25you need a lot of
01:06:26things. But for us, we
01:06:28are pay eighty percent of
01:06:30the star package, but, you
01:06:31really we get through. But
01:06:33I I think you I
01:06:34think we're we should we
01:06:36don't have to wait other
01:06:37people to say how good
01:06:38we are. We should think
01:06:39about we are doing well.
01:06:41I mean, is that is
01:06:42that right? I mean, it's
01:06:43the most important thing is
01:06:44a freedom. Right? We have
01:06:45the freedom
01:06:47to operate, to really
01:06:49control our own destiny. I
01:06:50think that in this day
01:06:51and age,
01:06:52if we have that freedom,
01:06:54it's always it's already applies.
01:06:56I was to consider this
01:06:57as a best recognition.
01:06:59But anytime
01:07:00you don't want I want
01:07:01I want the Edward School
01:07:02of Hospital taker
01:07:04receiver, you know, what's called
01:07:05receiver shape. Right? That will
01:07:07be in trouble. Somebody assigned
01:07:08to some administrator
01:07:09here, that would be done.
01:07:10Alright. So you I don't
01:07:12know answer your question, but
01:07:13I just say, I think
01:07:14we we should have feel
01:07:15we're doing well, but no
01:07:16no criticize as far as
01:07:18I know they are.
01:07:19Well, thank you. I mean,
01:07:20I think that's good, but
01:07:21sometimes, you know, it's good
01:07:23that maybe, you know, you're
01:07:24saying there is not a
01:07:25lot of recognition, but the
01:07:27recognition comes as, like, we
01:07:29we get to operate on
01:07:30our own terms. And I
01:07:32think
01:07:32Yeah. But a lot of
01:07:34You know? Yeah. A lot
01:07:35of the time, you know,
01:07:36when you do you run
01:07:38the department, your
01:07:39your cash flow is good,
01:07:41your budget is always in
01:07:43the black, and your achievement
01:07:44you achieve a lot of
01:07:45papers, you know, hopefully, you
01:07:47know, patents down the road.
01:07:49I don't really
01:07:50we need
01:07:52I don't think we really
01:07:53need anybody to say anything.
01:07:54Just leave us alone. So
01:07:55that's,
01:07:56I'm kind of.
01:07:58All right. Thank you. Thank
01:07:59you so much. Thanks, everyone.